Inhibikase Therapeutics, Inc. (IKT) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$51.97M | -81.8% |
| 2024 | -$28.59M | -42.3% |
| 2023 | -$20.09M | -10.8% |
| 2022 | -$18.13M | -22.8% |
| 2021 | -$14.77M | -423.9% |
| 2020 | -$2.82M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$51.97M | -81.8% |
| 2024 | -$28.59M | -42.3% |
| 2023 | -$20.09M | -10.8% |
| 2022 | -$18.13M | -22.8% |
| 2021 | -$14.77M | -423.9% |
| 2020 | -$2.82M | — |